MORGANTOWN, W.Va. – The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer.
Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and combinations of the cancer medications pegylated liposomal doxorubicin (PLD), atezolizumab, and bevacizumab in the treatment of ovarian cancer.
“We are excited to bring this clinical trial to West Virginia and the WVU Cancer Institute,” Dr. Galvan Turner said. “This treatment has the potential to allow for more options for patients for whom other treatments may not be effective.”
The clinical trial is open to epithelial ovarian cancer patients whose cancer recurred less than one year after completing their first treatment or line of chemotherapy and are considered platinum resistant.
All participants will receive treatment, but the types of treatment will be randomly assigned.
“The WVU Cancer Institute is dedicated to expanding the field of knowledge of cancer treatment,” Galvan Turner said. “We hope this study will help advance the field and provide more options for patients with ovarian cancer.”
Bonnie’s Bus, a 45-foot, state-of-the-art mobile mammography vehicle, will visit Randolph, Grant, Hampshire, and Mineral counties offering three-dimensional (3D) digital screening mammograms and breast care education to women.
The WVU Cancer Institute has joined the Gynecology Oncology Group (GOG) Foundation network to offer a larger portfolio of clinical trials to its patients.
Urinary incontinence is an embarrassing condition that can affect both men and women. The causes vary and require different approaches to treatment. The WVU Medicine urogynecology team has an option for patients whose urinary incontinence is related to the nervous system.